Abbott has launched its third test for coronavirus (COVID-19) and will start shipping it in the U.S.
The test is a serology test ―also called an antibody test―, which could be a critical next step in battling this virus.
Abbott’s test helps to detect the IgG antibody to SARS-CoV-2. An antibody is a protein that the body produces in the late stages of infection and may remain for up to months and possibly years after a person has recovered. Detecting these IgG antibodies will help determine if a person was previously infected with the virus that causes COVID-19.
The new antibody test is to be used on Abbott’s ARCHITECT i1000SR and i2000SR laboratory instruments, which can run up to 100-200 tests an hour.
Abbott is making the test available as part of the U.S. Food and Drug Administration’s notification without an Emergency Use Authorization (EUA) pathway that was outlined for COVID-19 diagnostic tests during the public health emergency. Abbott also plans to obtain CE mark in Europe.
Editorial Disclaimer: information published during the 2020 COVID-19 pandemic may be updated frequently to reflect the dynamic nature of current understanding.
- Roche develops new COVID-19 antibody test
- Siemens developing new diagnostic for COVID-19
- Hologic’s molecular test for SARS-CoV-2 receives FDA Emergency Use Authorization
- Commercially available COVID-19 diagnostic tests
- Cepheid molecular test for the qualitative detection of SARS-CoV-2